Grant Private Wealth Management Inc Sells 8,979 Shares of AbbVie Inc. $ABBV

Grant Private Wealth Management Inc cut its position in AbbVie Inc. (NYSE:ABBV) by 75.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,915 shares of the company’s stock after selling 8,979 shares during the quarter. Grant Private Wealth Management Inc’s holdings in AbbVie were worth $675,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Hobart Private Capital LLC grew its stake in shares of AbbVie by 4.4% in the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock valued at $261,000 after acquiring an additional 48 shares in the last quarter. Sivia Capital Partners LLC grew its position in shares of AbbVie by 1.1% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock worth $848,000 after purchasing an additional 51 shares in the last quarter. FF Advisors LLC increased its holdings in shares of AbbVie by 3.6% during the second quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock worth $286,000 after purchasing an additional 53 shares during the period. Landaas & Co. WI ADV raised its position in shares of AbbVie by 1.1% in the second quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock valued at $920,000 after buying an additional 53 shares in the last quarter. Finally, Bernardo Wealth Planning LLC raised its position in shares of AbbVie by 2.9% in the second quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company’s stock valued at $354,000 after buying an additional 53 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ABBV shares. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Scotiabank began coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Evercore ISI increased their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Finally, Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Stock Performance

NYSE:ABBV opened at $224.32 on Thursday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The stock’s 50-day simple moving average is $226.87 and its 200 day simple moving average is $210.61. The firm has a market capitalization of $396.47 billion, a PE ratio of 169.94, a price-to-earnings-growth ratio of 1.27 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.